Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: Mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisone

SpringerPlus

Volumn 2, Issue 1, 2013, Pages 1-10

  Lee, Chee Khoon ^a,e   Gebski, Val J ^a,e   Coates, Alan S ^a,b,e   Veillard, Anne Sophie ^a,e   Harvey, Vernon ^c,e   Tattersall, Martin H N ^a,e   Byrne, Michael J ^d,e   Brigham, Brian ^e   Forbes, John ^e   John Simes, R ^a,e  

^a UNIVERSITY OF SYDNEY   (Australia)

^b International Breast Cancer Study Group   (Switzerland)

^c AUCKLAND CITY HOSPITAL   (New Zealand)

^d SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^e UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Breast cancer; Chemotherapy; Quality of life; Randomized trial; Survival; Toxicity

Indexed keywords

EID: 84887265961     PISSN: None     EISSN: 21931801     Source Type: Journal    
DOI: 10.1186/2193-1801-2-391     Document Type: Article

References (20)

1. Bishop J, Gebski V, Simes R, Dewar J, Snyder R, Byrne M, Forbes J (1999) Sequential randomised studies in metastatic breast cancer: CMFP vs doxorubicin/cyclophosphamide, mitoxantrone or paclitaxel. Oncology 13(Supplementary 7):1-6.
2. Carrick S, Parker S, Thornton CE, Ghersi D, Simes J, Wilcken N (2009) Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 2, CD003372.
3. Chia SK, Speers CH, D'Yachkova Y, Kang A, Malfair-Taylor S, Barnett J, Coldman A, Gelmon KA, O'Reilly SE, Olivotto IA (2007) The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 110(5):973-979.
4. Chung CT, Carlson RW (2003) Goals and Objectives in the Management of Metastatic Breast Cancer. Oncologist 8(6):514-520.
5. Coates A, Gebski V, Bishop JF, Jeal PN, Woods RL, Snyder R, Tattersall MHN, Byrne M, Harvey V, Gill G, Simpson J, Drummond R, Browne J, van Cooten R, Forbes JF (1987) Improving the Quality of Life during Chemotherapy for Advanced Breast Cancer. New England Journal of Medicine 317(24):1490-1495.
6. Coates A, Glasziou P, McNeil D (1990) On the receiving end-III Measurement of quality of life during cancer chemotherapy. Ann Oncol 1(3):213-217.
7. Cornbleet MA, Stuart-Harris RC, Smith IE, Coleman RE, Rubens RD, McDonald M, Mouridsen HT, Rainer H, Van Oosterom AT, Smyth JF (1984) Mitoxantrone for the treatment of advanced breast cancer: Single-agent therapy in previously untreated patients. Treating the Patient, Not Just the Cancer 20(9):1141-1146.
8. Dafni U, Grimani I, Xyrafas A, Eleftheraki AG, Fountzilas G (2010) Fifteen-year trends in metastatic breast cancer survival in Greece. Breast Cancer Res Treat 119(3):621-631.
9. Gennari A, Conte P, Rosso R, Orlandini C, Bruzzi P (2005) Survival of metastatic breast carcinoma patients over a 20-year period. Cancer 104(8):1742-1750.
10. Ghersi D, Wilcken N, Simes J, Donoghue E (2005) Taxane containing regimens for metastatic breast cancer. Cochrane Database Syst Rev 2:1-75.
11. Glasziou PP, Simes RJ, Gelber RD (1990) Quality adjusted survival analysis. Stat Med 9(11):1259-1276.
12. Goodwin PJ, Black JT, Bordeleau LJ, Ganz PA (2003) Health-Related Quality-of-Life Measurement in Randomized Clinical Trials in Breast Cancer-Taking Stock. J Natl Cancer Inst 95(4):263-281.
13. Lord S, Ghersi D, Gattellari M, Wortley S, Wilcken N, Thornton CE, Simes J (2008) Antitumour antibiotic containing regimens for metastatic breast cancer. Cochrane Database Syst Rev 4:1-92.
14. Lumley T, Simes RJ, Gebski V, Hudson HM (2001) Combining components of quality of life to increase precision and evaluate trade-offs. Stat Med 20(21):3231-3249.
15. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47(1):207-214.
16. Priestman TJ, Baum M (1976) Evaluation Of Quality Of Life In Patients Receiving Treatment For Advanced Breast Cancer. Lancet 307(7965):899-901.
17. Simes R, Gebski V, Coates A, Forbes J, Harvey V, Van Hazel G, Tattersall M, Abdi E, Brigham B (1994) Quality of life with single agent mitozantrone or combination chemotherapy for advanced breast cancer, a randomised trial. Proceedings of the American Society of. Clin Oncol 13:73.
18. Spitzer WO, Dobson AJ, Hall J, Chesterman E, Levi J, Shepherd R, Battista RN, Catchlove BR (1981) Measuring the quality of life of cancer patients: A concise QL-Index for use by physicians. J Chronic Dis 34(12):585-597.
19. Stockler MR, Harvey VJ, Francis PA, Byrne MJ, Ackland SP, Fitzharris B, Van Hazel G, Wilcken NRC, Grimison PS, Nowak AK, Gainford MC, Fong A, Paksec L, Sourjina T, Zannino D, Gebski V, Simes RJ, Forbes JF, Coates AS (2011) Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer. J Clin Oncol 29(34):4498-4504.
20. Tannock IF (1987) Treating the Patient, Not Just the Cancer. New England Journal of Medicine 317(24):1534-1535.